Newsfeeds - Spark Newswire

6 minute read

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout

Today, 6:45 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)

ADTX

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

Today, 6:45 PM

Gainers

APOP

1 minute read

HC Wainwright & Co. Initiates Coverage On Histogen with Buy Rating, Announces Price Target of $2.4

By Benzinga Newsdesk

Today, 6:45 PM

HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Histogen (NASDAQ:HSTO) with a Buy rating and announces Price Target of $2.4.

HSTO

1 minute read

News

Histogen Says Received Letter From Nasdaq Indicating Co Did Not Meet Minimum Bid Price $1/Share

By Benzinga Newsdesk

Today, 6:45 PM

-SEC Filing

HSTO

6 minute read

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data

By Shanthi Rexaline

Today, 6:45 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19)

ABVC

1 minute read

Histogen Shares Additional Emricasan Data From COVID-19 Study

By Vandana Singh

Today, 6:45 PM

Histogen Inc (NASDAQ:HSTO) and its partner Amerimmune LLC have announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19…

HSTO

3 minute read

Histogen and Amerimmune Announce Additional Findings From Phase 1 Study Of Emricasan In Mild Symptomatic COVID-19 Patients; Says Emricasan Found To Have Statistically Significant Improvements In Clinically Relevant Hematological And Immune Markers

By Bill Haddad

Today, 6:45 PM

Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression Emricasan Found to Have Statistically Significant Improvements in Clinically Relevant Hematological and Immune Markers

HSTO